Abstract:Abstract Abstract 4501 Chronic graft-versus-host disease (GVHD) is a major complication of allogeneous hematopoietic stem cell transplantation, and it is regarded as a type of Th2 disease and seems to be a T-cell-mediated disorder in which immune tolerance to self-antigens is broken. Mesenchymal stem cells (MSCs) are multipotent cells which can extenuate refractory (GVHD) have been recently reported; however, the clinical data on MSC relieves chronic GVHD are generally lacking, and the machanisms remain to be investigated. One area of recent interest and controversy is the role of regulatory T cells (CD4+/CD25high T cells) in chronic GVHD. We examined the lymphocyte subsets and regulatory T cells of patients with refractory chronic GVHD were treated with basic immunosuppression plus MSCs derived from volunteer donors. Between April 2005 and October 2008, 19 patients were treated with their basic immunosuppression plus in vitro expanded bone-marrow-derived MSC as a compassionate treatment for resistant chronic GVHD. The median MSC dose given was 0.6×106/kg per body weight. Flow cytometric analysis was perfromed to analysis lymphocyte composition and activation at the time before MSC infusion(pre-MSC) and 3 months after MSC infusion (post-MSC). The study was approved by the Ethics Committee of the Guangdong General Hospital. All patients and the MSC donors provided written informed consent. In the present study, there were no significant changes in the proportion of T cells, B cells, NK cells and activation in no-response patients between pre-MSC and post-MSC. In the patients with response, the total lymphocyte was greater post-MSC transfusion than pre-MSC transfusion, and the proportion of CD4+ T cells were increased CD+8 T cells were decreased (the P value was 0.001 and 0.018, respectively). However, the proportion of CD4+CD25+ T cell and CD8+CD25+ T cells hadn't significantly changed post-MSC transfusion compared to pre-MSC infusion in patients with response. The T lymphocyte subsets of CD8+CD28+ cells, which are active CTLs that participate transplantation immunity and rejection reaction, were down-regulated when the chronic GVHD improved post-MSC infusion (P=0.023). By contrast, CD8+CD28- cells, which regulate cells to induce immune tolerance and inhibit antibody production and imbalance in the production of Th1 and Th2 cytokines, were increased in patients responsed to MSC infusion (P=0.025), and the ratio of CD8+CD28- cells to CD8+CD28+ was increased. Importantly, the increase of CD8+CD28- T cells and decrease of CD8+CD28+ T cells with improvement of cGVHD indicate that these factors may be involved in the development of chronic GVHD and that MSC suppresses chronic GVHD via modulation of the ratios of CD8+CD28- to CD8+CD28+ T cells. However, further immunological studies specifically addressing this issue are needed to confirm this possibility. This work was supported by Science and Technology Planning Project of Guangdong Province (2006B36005003,2007A032100003) and Science and Technology Planning Project of Guangzhou (2006Z2-E4071,2008A1-E4011-4,2008A1-E4011-5). Disclosures: No relevant conflicts of interest to declare.

A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD

Extracellular vesicles derived from mesenchymal stem cells prevent skin fibrosis in the cGVHD mouse model by suppressing the activation of macrophages and B cells immune response

Bone marrow mesenchymal stem cell-derived exosomes effectively ameliorate the outcomes of rats with acute graft-versus-host disease

CXCR4-transduced Mesenchymal Stem Cells Protect Mice Against Graft-Versus-host Disease.

Mesenchymal Stromal Cells Ameliorate Chronic GVHD by Boosting Thymic Regeneration in a CCR9-dependent Manner in Mice.

Mesenchymal Stem Cells ameliorate Chronic GVHD by Boosting Thymic Regeneration in a CCR9-dependent manner in mice

Mesenchymal stem cell exosome-derived miR-223 alleviates acute graft-versus-host disease via reducing the migration of donor T cells

Mesenchymal Stromal Cell (MSC)-Derived Combination of CXCL5 and Anti-CCL24 Is Synergistic and Superior to MSC and Cyclosporine for the Treatment of Graft-versus-Host Disease

hUCMSC-derived exosomes protect against GVHD-induced endoplasmic reticulum stress in CD4+ T cells by targeting the miR-16-5p/ATF6/CHOP axis

Exosomes Released From Human Bone Marrow–Derived Mesenchymal Stem Cell Attenuate Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Mice

Mesenchymal stem cell-derived exosomes can alleviate GVHD and preserve the GVL effect in allogeneic stem cell transplantation animal models

Phenotypical and Functional Characterization of Bone Marrow Mesenchymal Stem Cells in Patients with Chronic Graft-Versus-host Disease.

Immunologic Effects of Mesenchymal Stem Cells in the Treatment of Refractory Acute Graft-Versus-Host Disease

The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease.

MiR-223 Derived from Mesenchymal Stem Cell Exosomes Alleviates Acute Graft-Versus-Host Disease

Mesenchymal Stromal Cells Infusions Improve Refractory Chronic Graft Versus Host Disease Through an Increase of CD5+ Regulatory B Cells Producing Interleukin 10

Phase Ii Multicenter, Randomized, Double-Blind Controlled Study of Efficacy and Safety of Umbilical Cord-Derived Mesenchymal Stromal Cells in the Prophylaxis of Chronic Graft-Versus-Host Disease after Hla-Haploidentical Stem-Cell Transplantation

Immunomodulation Effects of Mesenchymal Stromal Cells on Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation

Mesenchymal Stem Cells Relieve Chronic GVHD Via Modulation the Ratio of CD8+CD28-/CD8+CD28+T Cells.

Improved efficacy of mesenchymal stromal cells stably expressing CXCR4 and IL-10 in a xenogeneic graft versus host disease mouse model

CCR7 Expressing Mesenchymal Stem Cells Potently Inhibit Graft-Versus-host Disease by Spoiling the Fourth Supplemental Billingham's Tenet.